Your browser is no longer supported. Please, upgrade your browser.
Settings
BMY Bristol-Myers Squibb Company daily Stock Chart
BMY [NYSE]
Bristol-Myers Squibb Company
IndexS&P 500 P/E21.27 EPS (ttm)2.65 Insider Own0.10% Shs Outstand1.66B Perf Week3.98%
Market Cap93.79B Forward P/E18.28 EPS next Y3.09 Insider Trans-2.63% Shs Float1.65B Perf Month13.91%
Income4.46B PEG1.48 EPS next Q0.75 Inst Own71.70% Short Float0.81% Perf Quarter0.46%
Sales19.43B P/S4.83 EPS this Y184.60% Inst Trans0.69% Short Ratio1.07 Perf Half Y-2.36%
Book/sh9.34 P/B6.04 EPS next Y10.01% ROA- Target Price55.18 Perf Year-8.21%
Cash/sh3.82 P/C14.77 EPS next 5Y14.33% ROE- 52W Range46.01 - 76.09 Perf YTD-2.78%
Dividend1.56 P/FCF- EPS past 5Y4.20% ROI- 52W High-25.82% Beta1.05
Dividend %2.76% Quick Ratio- Sales past 5Y-1.80% Gross Margin74.60% 52W Low22.67% ATR1.46
Employees25000 Current Ratio- Sales Q/Q22.30% Oper. Margin30.80% RSI (14)64.34 Volatility2.68% 2.56%
OptionableYes Debt/Eq- EPS Q/Q551.10% Profit Margin22.90% Rel Volume0.91 Prev Close55.77
ShortableYes LT Debt/Eq- EarningsJan 26 BMO Payout57.00% Avg Volume12.55M Price56.44
Recom2.40 SMA208.92% SMA502.82% SMA200-6.06% Volume11,365,881 Change1.20%
Dec-19-16Upgrade Jefferies Hold → Buy
Oct-28-16Reiterated Deutsche Bank Hold $59 → $52
Sep-09-16Reiterated Barclays Equal Weight $75 → $65
Aug-11-16Downgrade Berenberg Buy → Hold
Aug-08-16Reiterated Deutsche Bank Hold $68 → $62
Aug-08-16Downgrade Credit Suisse Outperform → Neutral $63
Aug-05-16Downgrade Morgan Stanley Overweight → Equal-Weight
May-23-16Initiated Hilliard Lyons Neutral
Apr-29-16Reiterated UBS Buy $73 → $80
Apr-29-16Reiterated Barclays Equal Weight $70 → $75
Apr-06-16Initiated Societe Generale Sell $48
Jan-22-16Upgrade Berenberg Hold → Buy
Dec-02-15Upgrade Guggenheim Neutral → Buy
Dec-01-15Reiterated Barclays Equal Weight $55 → $70
Aug-24-15Upgrade Piper Jaffray Underweight → Neutral
Jun-17-15Initiated Piper Jaffray Underweight $60
May-14-15Initiated Berenberg Hold $70
Apr-21-15Upgrade Morgan Stanley Equal-Weight → Overweight $60 → $80
Feb-27-15Reiterated Argus Buy $70 → $78
Jan-12-15Reiterated Argus Buy $62 → $70
Feb-24-17 07:01PM  Cramer: I'll Give You the Key to the Rally
01:04PM  BRISTOL MYERS SQUIBB CO Financials
07:27AM  Pharma Stock Roundup: Is BMY the Next Acquisition Target? Priority Review for PFE, Novartis Drugs
Feb-23-17 05:59PM  Final Trade: ORCL, AN & more
05:15PM  Eli Lilly & Co.s Revenues in 4Q16
04:15PM  Merck, Roche Gouge Bristol's I-O Share After Lung Cancer Approvals
02:25PM  Bristol-Myers Squibb Co (BMY) To Sell Senior Notes As Formidable Activist Investor Shows Interest at Insider Monkey
10:10AM  Company News for February 23, 2017
09:24AM  Januvia and Janumet: Merck & Co.s Blockbuster Diabetes Products
06:00AM  Why Do Stocks' Fair Value Estimates Change? at Morningstar
Feb-22-17 07:34PM  You'd be a fool to bet against the market now: Cramer
07:01PM  Cramer: Buyers for Bristol-Myers Are Few and Far Between
06:31PM  Cramer spells out why you would be a fool to bet against ...
06:21PM  Who Could Buy Bristol-Myers Squibb? at Motley Fool
06:00PM  Bristol-Myers Squibb Prices $1.5 Billion of Senior Notes Business Wire
05:13PM  Bristol Myers' Future Unsure as Carl Icahn Takes Stake
03:10PM  Exelixis (EXEL) Q4 Earnings: Is Positive Surprise in Store?
03:01PM  S&P 500 Trades Lower as Fed Signals Move on Rates 'Fairly Soon'
01:30PM  Heart-Thumping, Game-Changing Ways We're Treating Cardiovascular Disease at Motley Fool
01:04PM  US STOCKS-S&P, Nasdaq dip ahead of Fed minutes; Dow hits record high
12:50PM  Carl Icahn Takes Stake in Bristol-Myers Squibb at MarketWatch
12:33PM  This bullish stock signal has never been wrong and its about to flash for 2017 at MarketWatch
12:29PM  Carl Icahn just jumped into a $90 billion drug maker, and people are betting it'll be a takeover target
11:44AM  US STOCKS-Wall St slightly lower ahead of Fed minutes
10:57AM  Dow Turns Positive in Wishy-Washy Trading Ahead of Fed Minutes
10:33AM  Takeover speculation surrounds Bristol-Myers Squibb
10:00AM  DISH tunes in solid profits, Toll builds on earnings & Carl Icahn eyes Bristol-Myers Squibb
09:30AM  Bristol-Myers Squibb Company -- Moody's rates Bristol's notes A2; negative outlook at Moody's
09:08AM  Merck & Co.s Segment-Wise Revenues for 4Q16
08:55AM  Stock Futures Waver as Wall Street Awaits Clarity From the Fed
08:39AM  Carl Icahn's Next Target: Bristol-Myers Squibb at Forbes
08:07AM  Fed minutes in focus
08:03AM  Stock market set to lose grip on records as Fed minutes loom at MarketWatch
07:32AM  Is Carl Icahn Targeting Bristol-Myers Squibb for a Takeover? at Investopedia
05:36AM  U.S. stocks on pause after record rally, with Fed minutes ahead
02:07AM  Factor Xa's Win Billions of Dollars in Sales From Warfarin at Motley Fool
01:44AM  PRESS DIGEST - Wall Street Journal - Feb 22 Reuters
12:42AM  [$$] Carl Icahn Takes Stake in Bristol-Myers Squibb at The Wall Street Journal
Feb-21-17 07:49PM  [$$] Carl Icahn Takes Stake in Bristol-Myers at The Wall Street Journal
06:59PM  Can Carl Icahn Save Bristol Myers Squibb?
05:10PM  Carl Icahn Reportedly Invests In Potential Takeout Target Bristol-Myers
04:56PM  Icahn buys Bristol-Myers shares, adding to activist pressure
04:48PM  Icahn Takes Bristol-Myers Stake With M&A In Mind; Who Could Be The Acquirer?
04:11PM  Bristol-Myers Rises After Report That Carl Icahn Owns Stake
04:00PM  Carl Icahn takes stake in Bristol Myers: WSJ
03:51PM  Carl Icahn has reportedly taken a stake in Bristol-Myers and its shares are jumping
03:46PM  Icahn takes stake in Bristol-Myers: DJ
03:45PM  Icahn Purchases Stake in Bristol-Myers
02:30PM  Bristol-Myers Adds Three New Directors
02:13PM  Bristol-Myers Buys Back Shares, Shuffles Board
11:10AM  Bristol-Myers Squibb Co (BMY), Merck & Co., Inc. (MRK), And Other Pharmaceutical Firms All Targeting I-O Segment at Insider Monkey
08:18AM  BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statem
07:50AM  Bristol-Myers adds three directors in deal with Jana Partners
07:36AM  How Amgens Kyprolis Is Positioned in Second-Line Multiple Myeloma Segment
07:22AM  Bristol-Myers announces $2 bln accelerated share buyback; adds former Bausch & Lomb CFO, others to board at MarketWatch
06:59AM  Bristol-Myers Squibb Appoints Three New Independent Directors Business Wire
03:00AM  First Comprehensive Pediatric Hematology-Oncology Initiative Launched in Africa Business Wire
Feb-17-17 07:41PM  Merck, Bristol-Myers, Incyte Race For A Cure In $25 Billion I-O Market
07:34PM  These Are The First Immune-System Cancer Drugs OK'd By FDA
Feb-16-17 12:36PM  Top AstraZeneca shareholder Woodford adds to stake, bullish on outlook
12:06PM  David Tepper Invests Heavily in Pharma in 4th Quarter
11:41AM  How Bristol-Myers Squibb and Pfizer Are Winning a Big Brawl in Blood Thinners at Motley Fool
Feb-15-17 07:34PM  3 Stocks We're Watching in the First Quarter at Motley Fool
12:38PM  Bristol-Myers: Don't Bet on a Pfizer Acquisition at Barrons.com
11:19AM  Merck: There's Only One Way to Outperform Now at Barrons.com
10:41AM  Here Are The Major Moves Made By Bridgewater Associates Going Into 2017 at Insider Monkey
09:30AM  Markets Continue to Hit Record Highs: Today's Research Reports on Stocks to Watch Bristol-Myers Squibb and Himax Technologies Accesswire
Feb-14-17 03:33PM  Bristol-Myers Squibb: Takeover Target? at Barrons.com
Feb-13-17 05:17PM  Better Buy: Exelixis, Inc. vs. Bristol-Myers Squibb at Motley Fool
04:12PM  Tampa business leaders speak out on incentives, tourism marketing during Gov. Scott's visit (Video) at bizjournals.com
02:31PM  Bristol-Myers Squibb Company -- Moody's revises Bristol's outlook to negative; affirms A2/Prime-1 at Moody's
12:43PM  Baron Funds' Fifth Avenue Growth Fund Comments on Bristol-Myers Squibb Company
Feb-10-17 08:35AM  Are Short Sellers Doubting Trump by Hiking Bets in Major Pharma?
06:44AM  Pharma Stock Roundup: Allergan, GSK Top 4Q Earnings, Praluent Breather for Sanofi
Feb-09-17 06:44PM  [$$] Bristol-Myers Squibb Stock in Bargain Bin at Barrons.com
11:00AM  [$$] Brakes on the pathway to treating cancer at Financial Times
Feb-08-17 10:54AM  Bristol-Myers Squibb to Take Part in Leerink 6th Annual Global Health Care Conference Business Wire
10:17AM  Gilead Sciences & Bristol Myers: Two Wrongs Make a Right? at Barrons.com
Feb-06-17 09:55AM  Q4 Earnings Faring Well for Pharma ETFs
08:05AM  These 2 Factors Sent Bristol-Myers Squibb Co. Tumbling by 16% in January at Motley Fool
07:47AM  Bristol-Myers Leukemia Drug Fails Mid-Stage Study at Investopedia
Feb-03-17 05:28PM  Bristol-Myers' Injectable Opdivo Gets FDA Approval for mUC
04:29PM  AstraZeneca Shrugs Off Bristol-Myers' Setback; Crushes Q4 Views
01:03PM  Bristol-Myers' Opdivo Approved for Bladder Cancer at Investopedia
06:54AM  Pharma Stock Roundup: Pfizer, Merck, LLY Report Results, Teva Hit by Copaxone Ruling
Feb-02-17 04:15PM  Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma, a Type of Bladder Cancer Business Wire
03:13PM  U.S. FDA approves Bristol-Myers' Opdivo for bladder cancer Reuters
12:58PM  Lower Valuations Have Merck Looking 'Very Hard' at M&A Options
12:31PM  ETFs with exposure to Bristol-Myers Squibb Co. : February 2, 2017
12:25PM  [$$] Merck hails rise in patient tests for immunotherapy drug Keytruda at Financial Times
11:06AM  Roche Bets on New Drugs to Boost Sales at Investopedia
10:54AM  Roche (RHHBY) Beats on Earnings in 2016, Misses on Sales
09:21AM  Cancer Survivors Need More Efficient Integrated Long-Term Care and Stronger Policies Across Healthcare, Advocacy and the Workplace, New Research Concludes Business Wire
07:11AM  Merck Posts In-Line 4Q Earnings, Issues Cautious 2017 Sales Outlook
07:00AM  3 Pharmaceutical Stocks With Bigger Dividends Than Johnson & Johnson at Motley Fool
Feb-01-17 03:10PM  Spotlight on Keytruda as Merck Prepares to Unveil Fourth-Quarter Results
12:46PM  Dodge & Cox Comments on Bristol-Myers Squibb
12:42PM  Dodge & Cox's Stock Fund 4th Quarter Letter to Shareholders
12:19PM  Bristol-Myers Squibb Announces European Patent Office Decision on Sprycel Business Wire
10:35AM  Bristol-Myers Squibbs Valuation Compared to Its Peers
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. It offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; immunoscience; cardiovascular; and neuroscience. Its products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza and Sunvepra for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Opdivo, a fully human monoclonal antibody for non-small cell lung and renal cell cancer, and melanoma; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for metastatic melanoma; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Orencia to treat rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation. Its products pipeline includes Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; BMS-663068, an investigational compound that is being studied in HIV-1; and Prostvac, a Phase III prostate-specific antigen to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The company has clinical trial collaborations with Calithera Biosciences, Inc. and Janssen Biotech, Inc.; and a research collaboration with GeneCentric Diagnostics, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ANDREOTTI LAMBERTODirectorJan 30Option Exercise27.01100,0002,701,000957,931Feb 01 04:43 PM
Elicker John ESVP, Public Affairs & IRJan 03Option Exercise0.00950056,232Jan 05 04:37 PM
Bancroft Charles AEVP & Chief Financial OfficerDec 02Option Exercise0.006,4030192,801Dec 06 04:42 PM
Bancroft Charles AEVP & Chief Financial OfficerNov 01Option Exercise0.003,1000187,794Nov 03 05:21 PM
ANDREOTTI LAMBERTODirectorNov 01Option Exercise22.14305,9096,772,825998,777Nov 03 05:22 PM
Elicker John ESVP, Public Affairs & IRNov 01Option Exercise0.00494055,505Nov 03 05:21 PM
ANDREOTTI LAMBERTODirectorOct 11Option Exercise17.51368,7066,456,042692,868Oct 13 05:00 PM
ANDREOTTI LAMBERTODirectorSep 08Sale56.9710,800615,276323,699Sep 09 04:41 PM
ANDREOTTI LAMBERTODirectorSep 07Sale56.7710,800613,116334,499Sep 09 04:41 PM
Nielsen AnneChief Compliance & Ethics OffSep 03Option Exercise0.001,596029,722Sep 07 04:33 PM
ANDREOTTI LAMBERTODirectorAug 25Sale58.9211,600683,472345,299Aug 25 05:10 PM
ANDREOTTI LAMBERTODirectorAug 24Sale59.4311,600689,359356,899Aug 25 05:10 PM
Gordon MurdoEVP, Chief Commercial OfficerAug 01Option Exercise0.001,511015,250Aug 03 04:56 PM
ANDREOTTI LAMBERTODirectorJul 08Sale75.0411,600870,461368,499Jul 11 05:12 PM
ANDREOTTI LAMBERTODirectorJul 07Sale73.8611,600856,776380,099Jul 11 05:12 PM
Blin EmmanuelSVP, Chief Strategy OfficerJul 02Option Exercise0.00951012,516Jul 06 05:58 PM
Cuss Francis MEVP & CSOJul 01Option Exercise0.003,6550291,628Jul 06 05:58 PM
Gordon MurdoEVP, Chief Commercial OfficerJul 01Option Exercise0.002,335014,950Jul 06 05:58 PM
ANDREOTTI LAMBERTODirectorJun 29Sale72.799,800713,342392,194Jun 30 05:42 PM
ANDREOTTI LAMBERTODirectorJun 28Sale71.6713,400960,396390,394Jun 30 05:42 PM
Elicker John ESVP, Public Affairs & IRJun 14Sale72.6911,820859,21955,011Jun 16 04:31 PM
Bancroft Charles AEVP & Chief Financial OfficerMay 20Sale70.7930,2012,137,838184,694May 24 05:04 PM
Caldarella Joseph CSVP & ControllerMay 16Sale72.473,519255,00455,238May 17 04:46 PM
Caforio GiovanniChief Executive OfficerMay 05Option Exercise0.008,0400134,549May 09 04:42 PM
Caforio GiovanniChief Executive OfficerMay 03Option Exercise24.7950,4551,250,602145,958May 05 04:31 PM
Caforio GiovanniChief Executive OfficerMay 03Sale71.3134,5942,466,885117,118May 05 04:31 PM
ANDREOTTI LAMBERTODirectorMay 02Option Exercise26.04234,7206,112,787671,514May 04 05:28 PM
Schmukler Louis SPres., Global Mfg. & SupplyMay 02Sale71.9522,2181,598,65221,971May 04 05:28 PM
ANDREOTTI LAMBERTODirectorMay 02Sale71.88234,72016,870,792436,794May 04 05:28 PM
ANDREOTTI LAMBERTODirectorApr 05Sale66.0011,600765,626436,794Apr 06 04:18 PM
ANDREOTTI LAMBERTODirectorApr 04Sale65.7911,600763,216448,394Apr 06 04:18 PM
JUDGE ANN POWELLSVP, Global Human ResourcesApr 01Option Exercise0.001,554025,260Apr 05 04:59 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.0031,624055,059Mar 14 09:44 PM
Cuss Francis MEVP & CSOMar 10Option Exercise0.0037,1430300,492Mar 14 09:43 PM
ANDREOTTI LAMBERTODirectorMar 10Option Exercise0.00204,4470574,101Mar 14 09:43 PM
Elicker John ESVP, Public Affairs & IRMar 10Option Exercise0.0020,860074,177Mar 14 09:43 PM
Caldarella Joseph CSVP & ControllerMar 10Option Exercise0.0020,460067,864Mar 14 09:44 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.0031,406089,478Mar 14 09:42 PM
Caforio GiovanniChief Executive OfficerMar 10Option Exercise0.0060,6230132,906Mar 14 09:42 PM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0057,4840366,730Mar 14 09:42 PM
JUDGE ANN POWELLSVP, Global Human ResourcesMar 10Option Exercise0.0025,435032,069Mar 14 09:43 PM
Nielsen AnneChief Compliance & Ethics OffMar 10Option Exercise0.008,806059,091Mar 14 09:41 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0075,6180247,158Mar 14 09:41 PM
Blin EmmanuelSVP, Head of CommercializationMar 10Option Exercise0.0011,707013,498Mar 14 09:42 PM
Gordon MurdoSVP, Head of Worldwide MarketsMar 10Option Exercise0.0019,309019,608Mar 14 09:41 PM
CAMPBELL LEWIS BDirectorMar 08Option Exercise24.962,50062,4002,500Mar 10 04:36 PM
CAMPBELL LEWIS BDirectorMar 08Sale66.002,500165,0000Mar 10 04:36 PM
Caforio GiovanniChief Executive OfficerMar 06Option Exercise0.002,889079,627Mar 08 04:42 PM
Gordon MurdoSVP, Head of Worldwide MarketsMar 06Option Exercise0.001,28202,611Mar 08 04:43 PM
Nielsen AnneChief Compliance & Ethics OffMar 06Option Exercise0.00724050,821Mar 08 04:43 PM
Caldarella Joseph CSVP & ControllerMar 06Option Exercise0.001,931048,253Mar 08 04:43 PM
LEUNG SANDRAEVP, General CounselMar 06Option Exercise0.005,5740315,121Mar 08 04:41 PM
Elicker John ESVP, Public Affairs & IRMar 06Option Exercise0.001,043053,715Mar 08 04:41 PM
Cuss Francis MEVP & CSOMar 06Option Exercise0.003,0100269,043Mar 08 04:42 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 06Option Exercise0.002,391060,032Mar 08 04:40 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 06Option Exercise0.007,3240169,885Mar 08 04:40 PM
Blin EmmanuelSVP, Head of CommercializationMar 06Option Exercise0.0081901,553Mar 08 04:41 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 06Option Exercise0.002,528024,746Mar 08 04:40 PM
Caldarella Joseph CSVP & ControllerMar 04Sale64.6412,962837,91646,322Mar 07 05:41 PM